Verona Pharma
plc
("Verona Pharma" or the
"Company")
Notice of
Cancellation of Trading on Xetra
19 October 2016, Cardiff – Verona
Pharma plc (AIM: VRP.L), the drug development company focused on
first-in-class medicines to treat respiratory diseases, announces
that it has applied to cancel its secondary trading listing on
Xetra, a platform of the Frankfurt Stock Exchange.
The last day of trading shares in the Company on Xetra will be
24 November 2016.
-Ends-
For further information please
contact:
| Verona Pharma plc |
Tel: +44 (0)20 3283 4200 |
| Jan-Anders Karlsson, Chief Executive
Officer |
|
|
|
| N+1 Singer |
Tel: +44 (0)20 7496 3000 |
| Aubrey Powell / Jen Boorer |
|
|
|
| FTI Consulting |
Tel: +44 (0)20 3727 1000 |
Simon Conway /
Stephanie Cuthbert /
Natalie Garland-Collins |
|
Notes to Editors
About Verona Pharma plc
Verona Pharma plc is a UK-based clinical stage biopharmaceutical
company focused on the development of innovative prescription
medicines to treat respiratory diseases with significant unmet
medical needs, such as chronic obstructive pulmonary disease
(COPD), asthma and cystic fibrosis.
Verona Pharma's lead drug, RPL554, is a first-in-class drug in
Phase 2 trials as a nebulised treatment for acute exacerbations of
COPD in the hospital setting. The drug is a dual
phosphodiesterase (PDE) 3/4 inhibitor and therefore has both
bronchodilator and anti-inflammatory effects, which are essential
to the improvement of patients with COPD and asthma.
Verona Pharma is also building a broader portfolio of
RPL554-containing products to maximise its benefit to patients and
its value. This includes the very significant markets for
COPD and asthma maintenance therapy. The Company is also
exploring the potential of the drug in different diseases, such as
cystic fibrosis, where it is in pre-clinical testing and has
received a Venture and Innovation Award from the Cystic Fibrosis
Trust.